Johnson & Johnson (JNJ) stock has risen 52.8% over the past year, adding 5.0% in the last month but slipping 4.7% in the past week. Wall Street’s analysts are moderately bullish, forecasting a move from the current $247.02 to an average 12‑month target of about $273.93.
Behind this consensus sits a split view on how quickly growth can accelerate. Some see the latest quarter as solid but not yet transformational, while others believe the ramp‑up of new products can sustain double‑digit revenue growth toward the end of the decade.
Jason Gerberry of BofA, a 4‑star analyst ranked 258 out of 12,329 with a 60.2% success rate and 19.8% average return, reiterated a Hold on JNJ with a $263 price target. He credits a solid second quarter, with Pharma and MedTech posting mid‑single‑digit growth, but stays neutral as he wants clearer evidence that long‑term sales goals will be met.
Gerberry notes JNJ’s premium valuation requires “full buy‑in” on its long‑term targets, even as early data for Icotyde in psoriasis looks encouraging. He flags risks around key future revenue drivers like Carvykti, Rybrevant and Inlexzo, where competitive and data uncertainties could pressure consensus expectations and balance the risk‑reward profile.
On the bullish side, Terence Flynn of Morgan Stanley, ranked 763 out of 12,329 with a 59.3% success rate and 11.2% average return, reiterated a Buy and lifted his target to $294. He highlights JNJ’s second‑quarter beat, a raise in 2026 revenue guidance to around $101.1 billion and stronger margin outlook supported by cost efficiencies and a lower expected tax rate.
Flynn emphasizes management’s renewed confidence in achieving double‑digit revenue growth by the end of the decade, driven by 28 products and platforms each expected to surpass $1 billion in annual sales. He sees MedTech weakness as temporary and points to early momentum in the Icotyde launch, with strong prescription trends and payer coverage already exceeding half of commercial lives.
For investors, the message is that JNJ is executing well but still needs to prove that its new product cycle can fully offset competitive threats and justify its valuation. Those siding with Gerberry may prefer to wait for clearer growth signals, while Flynn’s camp sees the current pullback as a chance to buy into a long‑term growth story supported by raised guidance and a broad late‑decade product pipeline.
Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.